We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

5 hedge funds and large institutions have $1.12M invested in Viridian Therapeutics in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,733% more capital inflows, than outflows

Capital inflows: $1.3M | Capital outflows: $71K

400% more funds holding

Funds holding: 1 → 5 (+4)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

6.3% more ownership

Funds ownership: 0.26% → 6.56% (+6.3%)

Holders
5
Holders Change
+4
Holders Change %
+400%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Heartland Advisors
Heartland Advisors
Wisconsin
+$944K
2
PCM
Perkins Capital Management
Minnesota
+$332K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$10.6K
4
GSC
Ground Swell Capital
South Carolina
+$8.26K
5
UBS
UBS
Switzerland
+$7.08K

Top Sellers

Rank Fund Capital Flow
1
EEG
E.E. Geduld
-$71K

VRDN Hedge Fund Activity: Q3 2014 in Review

5 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2014, worth a combined $1.12M — up 1,473% from $71K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VRDN positions and 1 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Heartland Advisors, opening a new position worth an estimated $944K. The largest seller was E.E. Geduld, exiting entirely with an estimated $71K sold.

  • 5 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2014, up from 1 in Q2 2014.
  • Funds reported $1.12M of Viridian Therapeutics stock for Q3 2014, up 1,473% quarter-over-quarter.
  • 5 funds opened new Viridian Therapeutics positions in Q3 2014 and 1 closed out, a net change of +4 holders.
  • The largest Viridian Therapeutics buyer in Q3 2014 was Heartland Advisors, an estimated $944K added.
  • The largest Viridian Therapeutics seller in Q3 2014 was E.E. Geduld, an estimated $71K sold.

Based on aggregated 13F filings for Q3 2014.